Voltron therapeutics, inc., a lucius partners portfolio company, announces definitive proof of concept data for its second oncology candidate (vtx-0p4) in a prostate stem cell antigen (psca) related tumor study in combination with a checkpoint inhibitor (cpi) / anti-mpd-1

Study conducted at the massachusetts general hospital's vaccine and immunotherapy center demonstrated highly significant improvements in overall survival and other key endpoints vtx-0p4, in combination with a cpi, had a statistically significant improvement in survival versus a cpi alone key targets include urothelial, prostate, and renal cancers  vtx-0p4 produced a safety profile similar to that seen in the control group and without evidence of reactogenicity  new york, may 29, 2025 (globe newswire) -- voltron therapeutics, inc., a lucius partners portfolio company, announced today that data from study vtx-io-004 demonstrated clear proof-of concept for the self-assembling therapeutic, vtx-0p4, in the treatment of cancers over-expressing prostate stem cell antigen (psca).   vtx-0p4 is a novel, modular, protein-based therapy candidate designed to provide a specific therapeutic t cell mediated immunogenic response to psca-expressing tumors.
STEM Ratings Summary
STEM Quant Ranking